HEART FAILURE / RESEARCH LETTER
Eicosanoids in human heart failure: pilot study of plasma epoxyeicosatrienoic and dihydroxyeicosatrienoic acid levels
| 1 | Department of Cardiology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic |
| 2 | Center of Experimental Medicine, Institute of Clinical and Experimental Medicine, Prague, Czech Republic |
| 3 | Department of Medical Chemistry and Biochemistry, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic |
CORRESPONDING AUTHOR
Petr Kala
Department of Cardiology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, V Uvalu, 15000, Prague, Czech Republic
Department of Cardiology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, V Uvalu, 15000, Prague, Czech Republic
Submission date: 2022-10-18
Final revision date: 2023-01-12
Acceptance date: 2023-01-14
Online publication date: 2023-02-06
Publication date: 2023-03-01
Arch Med Sci 2023;19(2):513–517
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The role of eicosanoids, metabolites of arachidonic acid with cardio-renal activity, remains unclear in human heart failure (HF).
Material and methods:
We enrolled 50 patients with HF to measure plasma 14,15-EET and 14,15-DHET levels using commercial ELISA kits and compared them with 25 age- and sex-matched controls.
Results:
Both of the measured eicosanoids were significantly higher in the HF group: 14,15-EET (91.3 ±25.7 ng/ml vs. 64.95 ±35.4 ng/ml) and 14,15-DHET (10.58 ±2.06 ng/ml vs. 9.07 ±1.60 ng/ml), p for both < 0.001.
Conclusions:
We found that peripheral plasma eicosanoid (14,15-EET, 14,15-DHET) levels are raised in patients with HF compared to age- and sex-matched controls.
The role of eicosanoids, metabolites of arachidonic acid with cardio-renal activity, remains unclear in human heart failure (HF).
Material and methods:
We enrolled 50 patients with HF to measure plasma 14,15-EET and 14,15-DHET levels using commercial ELISA kits and compared them with 25 age- and sex-matched controls.
Results:
Both of the measured eicosanoids were significantly higher in the HF group: 14,15-EET (91.3 ±25.7 ng/ml vs. 64.95 ±35.4 ng/ml) and 14,15-DHET (10.58 ±2.06 ng/ml vs. 9.07 ±1.60 ng/ml), p for both < 0.001.
Conclusions:
We found that peripheral plasma eicosanoid (14,15-EET, 14,15-DHET) levels are raised in patients with HF compared to age- and sex-matched controls.
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.